CWP
FATE icon

Concord Wealth Partners’s Fate Therapeutics FATE Stock Holding History

Concord Wealth Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7
Closed -$71 – 1073
2022
Q4 		$71 Buy
+7
New +$131 ﹤0.01% 1233
2022
Q3 		– Sell
-19
Closed – – 479
2022
Q2 		$0 Sell
19
-361
-95% -$9.96K ﹤0.01% 1271
2022
Q1 		$15K Sell
380
-535
-58% -$20.7K ﹤0.01% 683
2021
Q4 		$54K Buy
915
+827
+940% +$46.9K 0.01% 442
2021
Q3 		$5K Buy
88
+76
+633% +$5.96K ﹤0.01% 578
2021
Q2 		$1K Buy
+12
New +$967 ﹤0.01% 963

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Concord Wealth Partners's FATE Position: Q1 2023 in Review

Concord Wealth Partners sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 7 shares — an estimated $71 sold.

Concord Wealth Partners first reported a position in FATE in Q2 2021 and held it in 6 quarters. The position peaked at $54K in Q4 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Concord Wealth Partners reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Concord Wealth Partners sold 7 Fate Therapeutics shares in Q1 2023, an estimated $71.
  • Concord Wealth Partners first reported a position in Fate Therapeutics in Q2 2021 and held it in 6 quarters.
  • Concord Wealth Partners's Fate Therapeutics position peaked at $54K in Q4 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Concord Wealth Partners's 13F filing for Q1 2023, filed 26 Apr 2023.